0
Summaries for Patients |

Treatment of Crohn Disease with Anti–Tumor Necrosis Factor Agent FREE

[+] Article and Author Information

The summary below is from the full report titled “Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. A Randomized Trial.” It is in the 19 June 2007 issue of Annals of Internal Medicine (volume 146, pages 829-838). The authors are W.J. Sandborn, P. Rutgeerts, R. Enns, S.B. Hanauer, J.-F. Colombel, R. Panaccione, G. D'Haens, J. Li, M.R. Rosenfeld, J.D. Kent, and P.F. Pollack.


Ann Intern Med. 2007;146(12):I-20. doi:10.7326/0003-4819-146-12-200706190-00160
Text Size: A A A

What is the problem and what is known about it so far?

Crohn disease is a chronic inflammatory bowel disease. It involves swelling and irritation of the lining of the digestive tract. Symptoms include diarrhea, fever, abdominal pain, weight loss, and fatigue. Patients with Crohn disease usually have signs and symptoms of illness that recur at intervals throughout their lives. Doctors use several drugs to treat recurring bouts of the disease. If symptoms are severe or if patients do not respond to other therapies, doctors may prescribe powerful new drugs called anti–tumor necrosis factor (anti-TNF) agents. Some patients who initially respond to an anti-TNF agent may develop tolerance to that agent, and it will no longer work for them. Other patients may have severe adverse effects that make them stop taking the anti-TNF agent. Few studies tell us whether it is worthwhile to try a second anti-TNF agent in patients who have already tried an anti-TNF agent.

Why did the researchers do this particular study?

To see whether a different anti-TNF agent, adalimumab, could induce remission in patients with Crohn disease who either lost response to or could not tolerate another anti-TNF agent, infliximab.

Who was studied?

325 adults with Crohn disease with moderate to severe signs and symptoms of the illness. All patients had responded to or were intolerant of infliximab in the past. At study entry, they either had recurring symptoms despite treatment with infliximab (lost response) or could no longer take it because of adverse effects.

How was the study done?

Researchers recruited patients from 52 sites in the United States, Canada, and Europe. They randomly assigned patients to receive adalimumab or placebo. Researchers, doctors, and patients did not know who received which treatment. Patients were followed for 4 weeks. The researchers then compared the number of patients with few signs and symptoms of active disease (for example, the number of patients in remission) between groups.

What did the researchers find?

At 4 weeks, more patients in the adalimumab group were in remission than those in the placebo group (21% vs. 7%). Approximately 1% to 2% of patients in each group discontinued treatment because of an adverse event.

What were the limitations of the study?

The trial duration was short. It did not test long-term maintenance of response. Also, it did not directly compare different anti-TNF agents to see whether 1 agent was better than another for treating disease.

What are the implications of the study?

Trying a second anti-TNF agent (adalimumab) may decrease disease activity in some patients with Crohn disease who either lose response to or cannot tolerate another anti-TNF agent (infliximab). Large, long-term trials are needed to see which anti-TNF agents best maintain remission.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)